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Ingestion of arsenic-contaminated drinking water is associated with an increased risk of several
cancers, including skin and bladder malignancies; but it is not yet clear whether such adverse
effects are present at levels to which the U.S. population is exposed. In New Hampshire,
detectable levels of arsenic have been reported in drinking water supplies throughout the state.
Therefore, we have begun a population-based epidemiologic case-control study in which
residents of New Hampshire diagnosed with primary squamous cell (n=900) and basal cell
(n= 1200) skin cancers are being selected from a special statewide skin cancer incidence survey;
patients diagnosed with primary bladder cancers (n=450) are being identified through the New
Hampshire State Cancer Registry. Exposure histories of these patients will be compared to a
control group of individuals randomly selected from population lists (n= 1200). Along with a
detailed personal interview, arsenic and other trace elements are being measured in toenail
clipping samples using instrumental neutron activation analysis. Household water samples are
being tested on selected participants using a hydride generation technique with high-resolution
inductively coupled plasma mass spectrometry. In the first 793 households tested, arsenic
concentrations ranged from undetectable (0.01 pg/l) to 180 pg/I. Over 10% of the private wells
contained levels above 10 pg/i and 2.5% were above 50 pg/i. Based on our projected sample size,
we expect at least 80% power to detect a 2-fold risk of basal cell or squamous cell skin cancer or
bladder cancer among individuals with the highest 5% toenail concentrations of arsenic. Environ
Health Perspect 1 06(Suppl 4):1047-1050 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl4/
1047-1050karagas/abstract.html
Key words: epidemiologic studies, case-control studies, nonmelanoma skin cancer,
squamous cell skin cancer, basal cell skin cancer, bladder cancer, arsenic, heavy metals,
exposure assessment
Introduction
\Arsenic is one of the eight metals and 22 a variety of ores and minerals. Humans are
agents listed by the Office of Solid Waste exposed to arsenic primarily through food,
and Emergency of the U.S. Environmental and in some regions, through drinking
Protection Agency (U.S. EPA) as a concern water. Arsenic also has been used for various
at Superfund sites and is naturally present in industrial purposes such as pesticides, wood
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preservatives, feed additives, and semicon-
ductor applications (e.g., gallium arsenide).
Patients were treated with arsenic-contain-
ing drugs such as potassium arsenite (e.g.,
Fowler solution) for benign skin conditions
in the 19th and early 20th century, but
arsenic is now rarely used medicinally (1).
In high concentrations (e.g., > 2000
pg/kg/day), arsenic is toxic to humans, and
among the reported long-term health effects
associated with nonfatal doses are vascular
diseases, diabetes, and cancers-specifically
cancers of the skin (basal cell and squamous
cell), lung, bladder, kidney, and liver. These
observations have been made among indi-
viduals exposed to arsenic occupationally or
through drinking water contamination or
pharmacologic uses (2). In humans, organic
arsenic compounds (e.g., arsenobetaine,
found in seafood) are not as toxic as inor-
ganic arsenic. The carcinogenic effects of
organic arsenic are uncertain, although there
was no apparent increase in skin cancers
among patients treated with organic arsenics
for syphillis (3).
Estimates of the dose-response relation-
ship between drinking water arsenic expo-
sure and cancer have been made from
studies conducted in a region of Taiwan
that had artesian well water highly contami-
nated with arsenic. In a well-known house-
hold prevalence survey of skin cancer (4)
published about 30 years ago, villages with
median water arsenic concentrations of 170,
470, and 800 pg/l had skin cancer preva-
lence rates of 26, 101, and 214 per 1000
persons, respectively (4). More recently,
Brown and colleagues (5) performed a
reanalysis of these data using a multistaged
model. A model that included both a linear
and quadratic term in dose improved the fit
only slightly; thus there was no definitive
conclusion regarding the actual shape of the
dose-response curve. Among the limitations
of the Taiwanese study are that data are pro-
vided for the median concentration for all
wells in a village, and in some villages con-
centrations varied considerably, i.e., from
nearly 0 to over 1200 pg/I. Of some reassur-
ance is that data from a study conducted in
Mexico (with similar limitations) (5) also
appeared to fit the model derived from
Taiwan data. Smith and colleagues (6)
modeled standardized mortality ratios of
bladder, liver, lung, and kidney malignan-
cies computed for the endemic region of
Taiwan using rates for the country at large
as the standard. A linear dose-response
relationship was suggested by their analysis.
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The risk models derived from the
Taiwanese data indicate that concentrations
below 50 pg/I (the current maximum con-
taminant level for drinking water in the
United States) may be carcinogenic.
Consequently, there is considerable debate
about what levels of arsenic are safe. Part of
the difficulty is that we have limited data
for the United States at levels found in the
United States. The assessment of cancer
risk at concentrations below 170 pg/I
required extrapolation (i.e., where actual
data do not exist) and estimates have dif-
fered to some extent based on model
assumptions (e.g., the point of intercept,
consideration of arsenic exposure through
food) and model choice (e.g., multistaged
model or linear regression). Nonetheless, a
small case-control study conducted in Utah
found some evidence of an increased risk of
bladder cancer in relation to drinking water
arsenic, and in this population water con-
centrations of arsenic were primarily in the
10 to 50 pg/l range (7). Previous ecologic
studies conducted in the United States have
not found an association between water lev-
els of arsenic and skin cancer occurrence
(8,9). These results are difficult to interpret
because each of the geographic areas studied
had a broad range of water arsenic concen-
trations. Additionally, one of the U.S.
studies (9) used mortality rates, which is a
poor measure of occurrence for skin cancer.
Therefore, to help clarify the risk of
cancer in relation to arsenic exposure in a
geographically defined U.S. population, we
began an epidemiologic case-control study
of nonmelanoma skin cancers in 1993 and
added bladder cancer to our investigation in
1995. Among our major objectives are to
evaluate whether arsenic exposure is related
to an increased risk of skin or bladder cancer
in the New Hampshire population, to study
methods of quantifying an individual's
arsenic exposure, and to examine the sources
and mechanisms of arsenic's presence in the
drinking water supply.
Study Design
New Hampshire Study
New Hampshire is a rural state with a pop-
ulation of about 1.1 million (1990 U.S.
Census) (10). Private water supplies serv-
ing fewer than 25 individuals or 15 house-
holds are not regulated as part of the U.S.
EPA Safe Drinking Water Act (11) but an
estimated one-third of the New Hampshire
population uses private water. Arsenic is
present in drinking water throughout the
state, with levels as high as 600 pg/I
detected though volunteer testing by the
State of New Hampshire Water Supply
and Pollution Control Commission; 5% of
private wells are estimated to contain
arsenic concentrations above 50 pg/l.
A population-based study of non-
melanoma skin cancer incidence is feasible
in New Hampshire because of the unique
availability of a statewide skin cancer reg-
istry. Nonmelanoma skin cancers are
excluded from virtually all central cancer
registries; therefore, epidemiologic studies
of these malignancies are sparse in the
United States and elsewhere. Yet non-
melanoma skin cancers are considered the
most common cancers in humans (12). As
part of our study, newly diagnosed basal
cell carcinomas (BCC) and squamous cell
carcinomas (SCC) of the skin are being
identified through a network of over 90%
of practicing dermatologists and all pathol-
ogy laboratories in New Hampshire and
bordering areas. Routine visits are made to
each physician's office and each pathology
laboratory. Records are reviewed for basic
demographic information, prior history of
skin cancer, and histologic type and
anatomic location of newly diagnosed
BCCs and SCCs of the skin. Although in
situ SCC (including Bowen's disease) is also
associated with arsenic exposure (13), we
were concerned that earlier staged lesions
may be more susceptible to selection fac-
tors, i.e., people with known arsenic expo-
sure may be more likely to seek medical
attention or the physicians themselves more
likely to biopsy and diagnose a lesion.
Therefore, our case-control study includes
only invasive SCC along with BCC.
We are randomly selecting a population-
control group of a comparable age and sex
distribution as the cancer cases from drivers'
license records (for those less than 65 years
of age) and from Medicare enrollment files
(for those 65 years of age and older). Among
the advantages of population-based control
groups (vs clinic or hospitalized patients
with other diagnoses) are that they are less
prone to biases and also permit inference
about exposure prevalence in the population
at large (14).
We were particularly interested in
bladder cancer in New Hampshire because
maps of cancer mortality for state economic
areas in the United States showed that blad-
der cancer mortality rates were in the high-
est 10% throughout the New England
states, including New Hampshire (15). A
case-control study conducted in Vermont
and New Hampshire approximately 20
years ago found that occupational exposure
in the textile and leather industries could
explain only part of this excess (15). For
our study, bladder cancers are ascertained
from the New Hampshire State Cancer
Registry, which operates a rapid reporting
system. By state law, practitioners are
required to provide an initial report of
cancer within 15 days after diagnosis, and a
definite report can follow within 120 days.
To be eligible for our study, both skin and
bladder cancer cases and controls must be
residents of New Hampshire and 25 to
74 years of age. Because our study includes
an individual biologic measure of arsenic
exposure, we have not sought surrogate
responses (e.g., from a spouse, close relative,
or friend) for deceased individuals.
Personal Interview
Those who agree to take part in the study
undergo an extensive in-person interview
covering residence, occupation, medical
history, lifestyle factors (e.g., use of
tobacco), and family history of cancer.
This enables us to control for potentially
confounding factors and to evaluate
whether other individual characteristics
(e.g., smoking) modify the association
between arsenic and skin or bladder cancer.
Also, we examine whether other factors
(e.g., occupational history) are contributors
to arsenic exposure.
Participants are asked to document each
place they have lived and to indicate the
type of water supply (private vs public) for
each residence. Interview questions relating
to their household water supply include the
type of water supply that serves their house-
hold (e.g., public water, shared well, private
well, or spring); the duration of use; type of
supply (for private water supplies; e.g., arte-
sian, shallow, or spring); how many glasses
of water per day are consumed in foods or
beverages from this drinking water supply;
and use of water filters (e.g., what type and
for how long).
Arenic Determinations
The latency period for arsenic and cancer
occurrence is not yet known, but is likely
several years if not decades. For this reason,
we sought a long-term individual measure
of exposure. Arsenic is rapidly cleared from
the blood and excreted in urine. Therefore,
arsenic concentration in these fluids will
reflect relatively recent exposure (e.g., in the
past several hours or a few days). Specific
forms of arsenic can be analyzed in urine
(e.g., inorganic and various methylated
forms), and the fraction of these forms in
urine may reflect individual differences in
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the ability to metabolize arsenic (16).
Arsenic accumulates in hair and nail tissue
by binding to sulffhydryl groups of keratin,
and for this reason, these tissues have been
used to trace arsenic poisoning. Toenail
clippings are routinely used in epidemio-
logic studies because they are relatively easy
to collect and are less susceptible to external
contamination than hair. Toenails provide
a larger sample than fingernails and take
longer to grow. In a sample of nurses tested
twice for arsenic and other trace elements 6
years apart, arsenic was among the most
highly correlated of the elements they ana-
lyzed (a correlation of greater than 0.5)
(17). Measurement of arsenic directly in
water samples is another alternative.
However, at the time our study began, we
were uncertain whether water concentra-
tions varied appreciability over time, i.e.,
seasonally or from year to year. Moreover,
water is only one potential source of expo-
sure. In our small pilot study, the overall
correlation between water and toenail con-
centrations of arsenic was 0.67 (18); how-
ever, half of the samples were drawn from
regions of New Hampshire known to have
relatively high water levels of arsenic. A sig-
nificant correlation between water concen-
trations and both hair and toenail levels of
arsenic was also recently reported by Chiou
and colleagues (19). In this study, genetic
polymorphism in the GSTMJ or GSTTI
loci, which had an effect on the metabolic
forms of arsenic in urine, did not affect nail
or hair concentrations.
For our case-control study, toenail
clipping samples are being analyzed for
arsenic and other trace elements by instru-
mental neutron activation analysis (INAA)
at the University of Missouri Research
Reactor (Columbia, MO) using a standard
comparison approach as described previ-
ously (20). This method reduces and possi-
bly eliminates external contamination.
Matrix-matched quality control samples,
having known arsenic content, and analyti-
cal blanks are analyzed with the samples
and standards. The detection limit for
arsenic measured by INAA is approxi-
mately 1 pg/I. An additional advantage to
INAA is that samples can be analyzed for
arsenic along with other trace elements
hypothesized in experimental studies to
interact with arsenic carcinogenesis (21)
(e.g., selenium, zinc).
Water samples are being tested using a
hydride-generation technique with a high-
resolution inductively coupled plasma mass
spectrometer (HR-ICP-MS) (22). Using
this approach, a quantitative estimate of
arsenic is obtained for 99 % of the water
samples. The instrument is a Finnigan
MAT Element (Bremen, Germany) HR-
ICP-MS. Although lower detection limits
are possible, the quantification limit for
samples was set to 0.01 pg/l (0.001 pg/l for
blanks) to avoid excessive washout times.
Levels below 1 pg/l are not suspected of
posing a health risk; therefore, from a prac-
tical perspective it may not be necessary to
measure arsenic at such trace levels.
However, we also are interested in the cor-
relation between toenail and water concen-
trations and arsenic is detectable in all nail
samples. Likewise, we are examining the
geographic distribution of arsenic in water
throughout the state.
Accurate quantification of arsenic
necessitates strict precautions against conta-
mination. All sample preparations and
analyses are carried out in a trace-metal
clean HEPA-filtered-air environment.
Commercially washed (mineral-free) high-
density polyethylene bottles meet U.S. EPA
standards for water collection (I-Chem,
Newcastle, DE); however, we are unaware
of any published data on the performance
of these bottles for arsenic determination.
Therefore, we prepared acid-washed poly-
ethylene bottles in our class 100 clean room
and initially used these on all households
with private wells and on a random sample
of those with public water. Commercial
bottles were used for the rest of the house-
holds because we expected a smaller frac-
tion of public water would have detectable
arsenic. Powderless latex gloves are worn
during the collection and bottles are kept in
a washed sealed plastic bag. Samples of cold
water are taken after running the tap for at
least 1 min to avoid metal precipitation in
the pipes. Samples are immediately placed
back into the sealed bag. Duplicate samples
are drawn on 10% of the households (every
10th interview) throughout the study, and
field blanks are performed quarterly by each
interviewer. To compare the performance
of the two bottle-washing methods, we
tested water from a sample of households
using both types. All bottles are labeled
with identification numbers that do not
reveal the case-control status of the study
participants or whether the sample was a
replicate from the same household. In
addition to these quality control samples,
analytical blanks and potential instrumen-
tal drifts are carefully monitored, and
instrument standardization and repro-
ducibility is performed with certified
standard reference materials.
Water Arsenic Results
In the 793 households tested to date
(Table 1), 41% reported using a private
well or spring (serving 15 or fewer house-
holds or less than 25 individuals). Arsenic
concentrations range from undetectable
(< 0.01 pg/l) to 180 pg/I. Over 25% of the
private wells contained more than 2 pg/l
of arsenic, over 10% were above 10 pg/I,
and 2.5% were over 50 pg/l. In a pre-
liminary analysis of the population
controls, we found that participants resid-
ing in the three major cities of New
Hampshire (Concord, Manchester, or
Nashua) had lower water arsenic on aver-
age (data not shown). However, partici-
pants from these areas comprise only
about 20% of our sample.
A preliminary analysis was performed
on the replicate samples tested thus far.
Simple random effects models were used
to calculate intraclass correlations for the
log transformed arsenic measurements
(23). The intraclass correlation coefficient
for replicate samples was 0.98 and did not
appear to differ by bottle type (i.e., labora-
tory cleaned or commercially cleaned con-
tainers). Given this high correlation, we
concluded that the bottle types yield
highly comparable and reliable results in
our laboratory.
Table 1. Preliminary data on water arsenic concentrations among New Hampshire study participants.
Type of water supply
Water arsenic, pg/I Private, %a Public, %b Total, %C
< 0.01 0.9 0.4 0.6
0.01-0.10 27.8 30.7 29.5
0.1 1-0.50 23.5 52.2 40.5
0.51-1.00 12.3 8.5 10.1
1.01-2.00 7.7 3.4 5.2
2.01-10.00 15.4 3.6 8.4
10.01-50.00 9.9 1.1 4.7
> 50.00 2.5 0.0 1.0
Total, all samples 100.0 100.0 100.0
&Households tested=324; range <0.01-180.09; median 0.42. bHouseholds tested=469; range <0.01-49.53;
median 0.17. cHouseholds tested=793; range <0.01-180.09; median 0.20.
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Sample Size and Study Power
Based on existing risk assessment models,
we expect that the relative risks of cancer
associated with low levels of arsenic expo-
sure may be relatively small (i.e., on the
order of 1.5-2.0). We expect to interview
about 1200 BCC cases, 900 SCC cases, 450
bladder cancer cases, and 1200 controls.
With this sample size, we anticipate 80%
power to detect an odds ratio of 1.6, 1.7,
and 1.9, respectively, for BCC, SCC, and
bladder cancer among individuals with the
highest 5% of toenail arsenic concentrations
with a significance level (alpha) of 0.05. At
an alpha of 0.10, the minimum detectable
odds ratios are 1.5, 1.6, and 1.8 for BCC,
SCC, and bladder cancer. The minimum
detectable odds ratios for the highest 2% of
arsenic concentrations are about 2.0 for
BCC and SCC and 2.5 for bladder cancer,
with an alpha of 0.05, and 1.9 and 2.3,
respectively, with an alpha of 0.10. We will
increase our study power by analyzing
continuous variables (i.e., arsenic concentra-
tions) on a continuous scale. For example,
the minimum detectable odds ratio for blad-
der cancer and the highest 2% of exposure is
1.75 based on a linear or quadratic model,
with 80% power and an alpha of 0.05.
Summary
We are conducting an epidemiologic study
to investigate the effects of drinking water
exposure to arsenic on risk of non-
melanoma skin and bladder cancer in a
U.S. population. To accomplish this, we
have specifically established a system of
identifying nonmelanoma occurrences in
the general population and utilize the New
Hampshire State Cancer Registry for blad-
der cancer. Using HR-ICP-MS and a
hydride-generation procedure, we are able
to reliably detect arsenic at concentrations
present in over 99% of samples tested. We
are also using a biologic measure of arsenic
exposure (toenail clippings) that, based on
our pilot work, is highly correlated with
water concentrations. We plan to further
evaluate the relation between water and toe-
nail levels in our larger study and to assess
the contribution of other sources of arsenic
exposure such as tobacco smoking and
occupation on toenail levels. Our analysis
of household water samples will also help
clarify the sources and mechanisms of
arsenic presence in the drinking water sup-
ply. As part of the study, we are establishing
a specimen bank of blood and tumor sam-
ples that can be used in future studies to
evaluate potential susceptibility genes or
tumor markers of arsenic exposure. Based
on the projected sample size, we expect that
our study will help fill important gaps in
our knowledge regarding the relation
between arsenic exposure and skin and
bladder cancer risk in the United States.
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